^
Association details:
| Biomarker: | RUNX1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
Published date:
11/01/2018
Excerpt:
The most frequently observed mutations in the 5 responding patients were TET2 in 3 patients and ASXL1, DNMT3A, and RUNX1 in 2 patients each...In this ongoing phase II trial, preliminary data suggest that azacitidine and pembrolizumab was relatively safe and may have antitumor activity in patients who failed HMA.
Secondary therapy:
azacitidine
DOI:
doi.org/10.1182/blood-2018-99-115720
